NCT02564523View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

1,075

Participants

Timeline

Start Date

November 6, 2015

Primary Completion Date

February 12, 2019

Study Completion Date

February 12, 2019

Conditions
Hemorrhagic Fever, Ebola
Interventions
BIOLOGICAL

Ad26.ZEBOV

One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)

BIOLOGICAL

MVA-BN-Filo

One 0.5 mL IM injection of (1x10\*8 infectious units)

BIOLOGICAL

Placebo

One 0.5 mL IM injection of 0.9% saline

Trial Locations (7)

Unknown

BoboDioulasso

Ouagadougou

Abidjan

Toupah/Ousrou

Nairobi

Entebbe

Kampala

All Listed Sponsors
collaborator

EBOVAC2 Consortium

INDUSTRY

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Centre Muraz

OTHER

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT02564523 - Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults | Biotech Hunter | Biotech Hunter